Advertisements



Novartis (NVS) Announces Positive Data on Heart Failure Drug

Novartis AG.....»»

Category: topSource: zacksMar 20th, 2017

Novartis (NVS) Announces Positive Data on Heart Failure Drug

Novartis AG.....»»

Category: topSource: zacksMar 20th, 2017

Novartis (NVS) Presents Positive Data on Cardiovascular Drug

Novartis (NVS) presented new analysis from the PARADIGM-HF study on Entresto at a scientific meeting of the Heart Failure Society of America. Novartis AG NVS announces new analysis from the PARADIGM-HF study on its cardiovascular drug, Entresto.....»»

Category: topSource: zacksSep 19th, 2016

Novartis Offers Positive Data on Cardiovascular Drug Entresto

Novartis (NVS) announces new analysis from the PARADIGM-HF study on Entresto at a scientific session of the American Heart Association. Novartis AG NVS announced new analysis of the PARADIGM-HF study on its cardiovascular drug, Entresto, at a s.....»»

Category: topSource: zacksNov 16th, 2016

Novartis" Acute Heart Failure Drug Fails in Late-Stage Study

Novartis AG NVS .....»»

Category: futuresSource: nasdaqMar 22nd, 2017

Novartis" Acute Heart Failure Drug Fails in Late-Stage Study

Novartis AG (NVS) re.....»»

Category: topSource: zacksMar 22nd, 2017

Novartis Offers Positive Data on Breast Cancer Drug LEE011

Novartis (NVS) announced results from the phase III MONALEESA-2 study on LEE011 for the treatment of first-line HR+/HER2- advanced breast cancer. Shares of Novartis AG NVS gained 3.2% after the company announced encouraging data from a phase II.....»»

Category: topSource: zacksDec 12th, 2016

Novartis/Amgen Migraine Drug Positive in Phase III Study

Novartis (NVS) and Amgen (AMGN) migraine treatment AMG 334 hit the primary endpoint in the second phase III episodic migraine study. Novartis AG NVS and partner Amgen Inc. AMGN announced positive top-line data from the second pivotal phase III .....»»

Category: topSource: zacksNov 18th, 2016

Boston Scientific (BSX) Reports Positive Data on HeartLogic

Boston Scientific (BSX) recently announced positive data from the first clinical trial on the HeartLogic Heart Failure Diagnostic Service to detect impending heart failure decompensation. Boston Scientific Corporation BSX recently announced po.....»»

Category: topSource: zacksNov 17th, 2016

Novartis Offers Positive Data on Cardiovascular Drug Entresto

Zacks.....»»

Category: topSource: redinewsNov 16th, 2016

Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study

Novartis (NVS) announced positive top-line data from the phase III ASCEND-4 study on Zykadia to treat patients with ALK+ NSCLC. Novartis AG NVS announced positive top-line data from a phase III study (ASCEND-4) on its oncology drug, Zykadia, fo.....»»

Category: topSource: zacksSep 23rd, 2016

Novartis Says MS Drug Cut Risk of Disability Advance in Study

"These data are a positive stride forward," says Novartis CMO. Novartis’s investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease versus a placebo, the Swiss company sa.....»»

Category: europeSource: fortuneSep 17th, 2016

Novartis Reports Positive Phase II Data on Migraine Drug

Novartis AG (NVS) announced results from a phase II study on migraine candidate AMG 334. Novartis AG NVS announced results from a phase II study on migraine candidate AMG334.Data from the study were presented at the fifth European Headache and .....»»

Category: topSource: zacksSep 16th, 2016

Novartis (NVS) Reports Positive Data on Ultibro Breezhaler

Novartis Pharma AG (NVS) announced positive results from a head-to-head study, FLAME, on COPD drug Ultibro Breezhaler. Novartis Pharma AG NVS announced positive results from a head-to-head study, FLAME, on Ultibro Breezhaler at the 2016 Europe.....»»

Category: topSource: zacksSep 6th, 2016

US Dollar Left Vulnerable as Trump Trade Narrative Unravels

DailyFX com Fundamental Forecast for the US Dollar Neutral Healthcare reform failure struck at the heart of the Trump trade US Dollar vulnerable to deeper losses as rate hike prospects dim Data flow unlikely to inspire follow.....»»

Category: futuresSource: nasdaqMar 25th, 2017

Novartis Breast Cancer Drug OK"d by FDA as First-line Therapy

Novartis AG (NVS) announced that the FDA has approved Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, .....»»

Category: topSource: zacksMar 14th, 2017

Novartis (NVS) Reports Positive Data on Biosimilar Humira

Novartis AG (NVS) announced encouraging data for its proposed biosimilar verison of AbbV.....»»

Category: topSource: zacksMar 7th, 2017

Novartis (NVS) Reports Positive Data on Biosimilar Humira

Zacks.....»»

Category: topSource: redinewsMar 7th, 2017

ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update

Key updates Major progress in the QR-010 development program for CF with presentation of positive clinical data at North American CF conference in October 2016 On tra.....»»

Category: earningsSource: benzingaFeb 28th, 2017

Cytokinetics will sell percentage of royalties on heart failure drug for $90 million

The late-stage drug is being developed by Amgen and Cytokinetics......»»

Category: topSource: marketwatchFeb 2nd, 2017

Why This Seizure Drug Matters So Much for Marinus Pharma

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) saw its shares climb on Monday after the company reported positive preliminary results from its mid-stage trial. Specifically the data came from Mirna‚Äôs........»»

Category: blogSource: 247wallstJan 23rd, 2017